Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...
BESREMi is a preferred, FDA-approved option for both symptomatic low- and high-risk polycythemia vera patients. In the polycythemia vera space, BESRE ...
Merck KGaA’s U.S. pharma arm has recruited actor Selma Blair for a collaboration around multiple sclerosis treatment Mavenclad. | No cruel intentions here: Merck KGaA’s U.S. pharma arm has recruited ...
“Partnering with Genesis Therapeutics presents a unique opportunity to leverage their AI technologies to accelerate the ...
Injectable Drug Delivery MarketThe global injectable drug delivery market is estimated to be valued at USD 49.44 billion in 2024, with strong growth expectations due to advancements in healthcare, ...
U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...
TD Cowen made a significant adjustment to its stance on Merck (NSE:PROR) shares, downgrading the pharmaceutical giant from "Buy" to "Hold". Accompanying the downgrade, the firm also revised its price ...
Comments: Keytruda sales were $7.8 billion in the quarter, up 19%, driven by continued global demand from metastatic indications, including increased uptake in bladder and endometrial cancers, as well ...
The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telix’s portfolio, along with other novel targets currently in the discovery stage.
Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines. Click for more on MRK Q4 earnings.
Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products.
That R&D takes place not only at big pharma companies—household names such as Pfizer and Merck—but also at smaller, less well-known but no less heroic biosciences startups, such as Vivek ...